Gilead Sciences CEO O’Day sells $19.7 million in company shares

On November 4 and 5, 2026, Daniel O’Day, the CEO of Gilead Sciences, sold approximately $19.7 million worth of company shares. The sales were executed in accordance with a pre-established Rule 10b5-1 trading plan. Simultaneously, O’Day exercised stock options, buying shares totaling around $8.1 million. On November 4, he sold 102,619 shares priced between $175.05 and $175.35 per share.

The next day, November 5, he sold an additional 9,810 shares at an average price of $175.17 per share, totaling around $19,693,438. The sale prices were close to Gilead’s 52-week high of $176.58, with the stock having returned 39% year-to-date. However, experts suggest the stock might be overvalued at the moment. Concurrently, O’Day purchased 112,429 shares through option exercises, acquiring them at $72.34 each, worth about $8,133,113.

Now, he holds 551,683 shares directly and retains 128,310 non-qualified stock options, expiring on March 10, 2030, with a vesting schedule over four years. Gilead Sciences reported strong quarterly results, generating $8.3 billion in revenue, exceeding analyst estimates by 6%, and earning $2.55 per share, surpassing expectations by 15%.

This marks the company's strongest growth in over a decade, with a 16% increase year-over-year. Investment firms UBS, TD Cowen, and BMO Capital recently raised their price targets for Gilead Sciences, citing robust performance in the HIV portfolio and liver products, as well as a higher gross margin. Analysts remain optimistic about Gilead's financial health and growth prospects.